Evidence map›Paper›PMID 19295335›Full record

ReviewJournal of acquired immune deficiency syndromes (1999)2009

Cardiovascular complications in HIV management: past, present, and future.

Judith A Aberg

Erratum issuedAbstract readReview
In one paragraph

Review in Journal of acquired immune deficiency syndromes (1999), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Observational
  12. Article
  13. Article
  14. Article
  15. Brachial and central blood pressure in HIV-infected subjects.Hypertension research : official journal of the Japanese Society of Hypertension · 2015
    Article
  16. Review
  17. Article
  18. QT dispersion in HIV-infected patients receiving combined antiretroviral therapy.Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc · 2014
    Article
  19. Article
  20. Heart rate variability and heart rate turbulence in HIV-infected patients receiving combination antiretroviral therapy.Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc · 2013
    Article
4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

1 author.

Judith A AbergAIDS Clinical Trials Unit, Bellevue Hospital Center, New York University School of Medicine, New York, NY 10016, USA. judith.aberg@nyumc.org

Funding

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
AIDS Clinical Trials Group NetworkU01AI068636 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI KURITZKES, DANIEL R. · 2006 to 2010
$147.1M
New York University HIV/AIDS Clinical Trial UnitU01AI069532 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ABERG, JUDITH ANN · 2007 to 2011
$7.5M
New York University HIV/AIDS Clinical Trial UnitUM1AI069532 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ABERG, JUDITH ANN · 2012 to 2014
$2.9M
NIAID NIH HHS AI-AI068636NIAID NIH HHS U01 AI068636NIAID NIH HHS U01 AI069532NIAID NIH HHS UM1 AI068636NIAID NIH HHS UM1 AI069532
6 · The paper itself

Abstract

Highly active antiretroviral therapy (HAART) has significantly improved the prognosis for many individuals with HIV infection. Consequently, HIV infection has become a chronic and manageable disease. The focus on long-term management of patients with HIV infection has broadened to include comorbid conditions, most notably cardiovascular disease. Patients with HIV infection share many cardiovascular risk factors with the general population, and HIV infection itself may increase cardiovascular risk. Changes in lipid profiles associated with increased cardiovascular risk that have been observed with some HAART regimens have been a cause for concern among clinicians who treat HIV-infected patients. However, the lipid effects of HAART seem to depend on the type and duration of regimens employed. They can be managed effectively according to current guidelines that recommend lifestyle changes (eg, improved diet, increased exercise, smoking cessation) and pharmacologic therapy described in established treatment paradigms for patients on antiretroviral therapy and similar to measures currently used by the general population. A review of the clinical data indicates that the virologic and immunologic benefits of HAART clearly outweigh any metabolic effects observed in some patients over time and that preexisting, established cardiovascular risk factors contribute significantly to the potential development of cardiovascular events. These benefits of antiretroviral therapy have been demonstrated in studies comparing the superior efficacy of continuous vs. intermittent HAART.

Indexed as

Anti-HIV AgentsAntiretroviral Therapy, Highly ActiveCardiovascular DiseasesHIV InfectionsHumansLipid MetabolismLipidsRisk FactorsAnti-HIV AgentsLipids

Identifiers

PMID19295335
PMCPMC2746916

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.